Renaissance Capital logo

JNCE News

Biotechs stage comeback after slow quarter

Jounce Therapeutics logo

The US IPO market snapped back in the 1Q17, but quarterly biotech activity fell to its lowest level since the 4Q12. Just three of the 25 deals came from biotechs in the 1Q17, compared to seven of the eight in the 1Q16. Recent IPO Tocagen (TOCA)...read more

US IPO Weekly Recap: AppDynamics taken out, 6 IPOs price

APPD

The star was taken, but the show must go on. Six companies went public this week, but AppDynamics (APPD) was notably missing as Cisco (Nasdaq: CSCO) acquired it for $3.7 billion the night before its scheduled pricing. Cisco paid a 68%...read more

Jounce Therapeutics prices upsized IPO at $16 to advance cancer immunotherapies with Celgene

Jounce Therapeutics logo

Jounce Therapeutics, an early-stage biotech developing T cell immuno-oncology therapies with Celgene, raised $102 million by offering 6.4 million shares at $16, above the range of $13 to $15. Jounce Therapeutics plans to list on the Nasdaq under the symbol...read more

US IPO Week Ahead: AppDynamics headlines rush of 8 IPOs

APPD

There are eight IPOs scheduled for the week ahead, which would tie the most active week of 2016. Software provider AppDynamics (APPD) leads the pack; as the ...read more